[
  {
    "ts": null,
    "headline": "Tracking Bridgewater Associates 13F Portfolio - Q3 2025 Update",
    "summary": "Get a 2025 update on Bridgewater Associatesâ $25.53B portfolio, top stock moves, and diversification strategies.",
    "url": "https://finnhub.io/api/news?id=61d8296e69b080fa1b002c2b3fd9c2349cb2b455745d094b9d4ee71ffbc1a8f7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763931272,
      "headline": "Tracking Bridgewater Associates 13F Portfolio - Q3 2025 Update",
      "id": 137585679,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1333504671/image_1333504671.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Get a 2025 update on Bridgewater Associatesâ $25.53B portfolio, top stock moves, and diversification strategies.",
      "url": "https://finnhub.io/api/news?id=61d8296e69b080fa1b002c2b3fd9c2349cb2b455745d094b9d4ee71ffbc1a8f7"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Dissects Kimberly-Clark’s Acquisition of Kenvue",
    "summary": "Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently offered insights on. Cramer discussed the company’s planned acquisition of Kenvue during the episode. He said: “Alright, this is one we’ve talked about a bunch, Kimberly-Clark’s bold, nearly $49 billion bid to buy Kenvue, which is the J&J’s old over-the-counter business that makes Tylenol, […]",
    "url": "https://finnhub.io/api/news?id=9ee9d64465e585c68c9d8ae394f2c9d6609da10dbc2c2dec8432995da4923ea9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763927498,
      "headline": "Jim Cramer Dissects Kimberly-Clark’s Acquisition of Kenvue",
      "id": 137586717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently offered insights on. Cramer discussed the company’s planned acquisition of Kenvue during the episode. He said: “Alright, this is one we’ve talked about a bunch, Kimberly-Clark’s bold, nearly $49 billion bid to buy Kenvue, which is the J&J’s old over-the-counter business that makes Tylenol, […]",
      "url": "https://finnhub.io/api/news?id=9ee9d64465e585c68c9d8ae394f2c9d6609da10dbc2c2dec8432995da4923ea9"
    }
  }
]